NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
72 trialsNCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT05678205 2025-07-30
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Artiva Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT06592664 2025-06-06
FORTIFIDE
Lisata Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT04976660 2025-03-18
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
Portage Biotech
Phase 1/2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03764137 2025-01-31
Panitumumab
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT05610826 2024-10-26
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
University of Chicago
Phase 1/2 Withdrawn
NCT06006286 2024-08-26
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05898828 2024-08-05
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT05153304 2024-06-10
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
University of California, San Diego
Phase 1/2 Withdrawn
NCT04614766 2024-04-29
SPORE-3
University of Iowa
Phase 1/2 Withdrawn
NCT03127124 2024-04-02
QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
NantPharma, LLC
Phase 1/2 Withdrawn
NCT04751955 2023-10-31
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Korean Cancer Study Group
Phase 1/2 Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT05092750 2023-09-28
Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT03991104 2023-09-21
SOX-based CRT for Esophageal Cancer.
Zhejiang Provincial People's Hospital
Phase 1/2 Withdrawn
NCT05109052 2023-07-13
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
Phase 1/2 Withdrawn
NCT02344810 2023-05-25
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 1/2 Withdrawn
NCT05251038 2023-05-11
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT05628545 2023-01-18
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Guangdong GD Kongming Biotech LLC
Phase 1/2 Withdrawn
NCT05433402 2022-10-27
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
Sadat City University
Phase 1/2 Withdrawn
NCT03634683 2022-06-30
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Lion TCR Pte. Ltd.
Phase 1/2 Withdrawn
NCT05104905 2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2 Withdrawn
NCT05181865 2022-02-07
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Flame Biosciences
Phase 1/2 Withdrawn
NCT05080621 2022-01-05
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2 Withdrawn
NCT04105062 2021-12-09
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
Phase 1/2 Withdrawn
NCT01960023 2021-10-27
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
NSABP Foundation Inc
Phase 1/2 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT02038699 2021-04-30
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 1/2 Withdrawn
NCT03576963 2021-04-05
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Withdrawn
NCT01097239 2020-11-20
Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
Imperial College London
Phase 1/2 Withdrawn
NCT01302613 2020-08-20
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT02723942 2020-07-16
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT03739801 2020-03-27
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
University of Southern California
Phase 1/2 Withdrawn
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT04158700 2020-02-19
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Withdrawn
NCT01923233 2020-01-22
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT01995227 2020-01-22
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Mirror Biologics, Inc.
Phase 1/2 Withdrawn
NCT02449967 2019-09-12
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT03778879 2019-07-19
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
University of Rochester
Phase 1/2 Withdrawn
NCT03697239 2019-06-11
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
University of California, San Diego
Phase 1/2 Withdrawn
NCT03797443 2019-05-31
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Piedmont Cancer Institute
Phase 1/2 Withdrawn
NCT03908333 2019-05-30
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT03182894 2018-08-28
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 1/2 Withdrawn
NCT03307603 2018-02-27
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT02722551 2018-01-09
RELIEF
Edwards Lifesciences
Phase 1/2 Withdrawn